GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

LXRX · Sep 30, 2024

LEXICON PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001062822-24-000060General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

17.63% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-3079.78% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

36.53% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

95.92% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-3658.41% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1480.76% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

160.83% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History10 statesHistory building
Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20240/7 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20250/7 normalizedLevel 3Sep 30, 20250/8 normalizedLevel 3Dec 31, 20250/9 normalizedLevel 3Mar 31, 20266/8 normalizedLevel 3Jun 30, 20266/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
15.46%
Current
17.63%
Delta
2.17%
Cash Generation Decreased
Previous
-3001.86%
Current
-3079.78%
Delta
-77.93%
Inventory Pressure Increased
Previous
36.18%
Current
36.53%
Delta
0.35%
Margin Increased
Previous
89.73%
Current
95.92%
Delta
6.19%
Profitability Decreased
Previous
-3423.25%
Current
-3658.41%
Delta
-235.16%
R And D Intensity Increased
Previous
1091.09%
Current
1480.76%
Delta
389.66%
Sbc Intensity Decreased
Previous
303.03%
Current
160.83%
Delta
-142.20%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · LXRX Fundamental State →Has State · LEXICON PHARMACEUTICALS, INC. →Transitioned To · LXRX Fundamental State →Transitioned To · LXRX CAPEX_INTENSITY_INCREASED →Transitioned To · LXRX CASH_GENERATION_DECREASED →Transitioned To · LXRX INVENTORY_PRESSURE_INCREASED →Transitioned To · LXRX MARGIN_INCREASED →Transitioned To · LXRX PROFITABILITY_DECREASED →Transitioned To · LXRX R_AND_D_INTENSITY_INCREASED →Transitioned To · LXRX SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.